{"id":"cell-line-and-virus","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL6068580","moleculeType":"Cell"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Cell lines and viruses are biological materials used in pharmaceutical development, vaccine production, or research rather than drugs with specific receptor or enzyme targets. Without additional context on the specific cell line type, virus species, or intended use, the mechanism cannot be precisely defined. Phase 2 development suggests this may be a viral vector-based therapy or cell therapy candidate.","oneSentence":"This is a cell line and virus preparation used as a research or therapeutic tool, not a traditional pharmaceutical drug with a defined molecular mechanism.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:50:35.527Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT04534205","phase":"PHASE2, PHASE3","title":"A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2021-01-07","conditions":"Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer","enrollment":350},{"nctId":"NCT06391814","phase":"NA","title":"Donor-Derived EBV-Specific T Cells for Life Threatening EBV-lymphoma (OLIP-EBV-TCL-01-HMR01)","status":"COMPLETED","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2024-01-16","conditions":"EBV Associated Lymphoma","enrollment":1},{"nctId":"NCT05945485","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-16","conditions":"Influenza","enrollment":50},{"nctId":"NCT04554914","phase":"PHASE2","title":"A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases","status":"RECRUITING","sponsor":"Pierre Fabre Medicament","startDate":"2021-07-14","conditions":"Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD)","enrollment":190},{"nctId":"NCT06072612","phase":"PHASE3","title":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","status":"RECRUITING","sponsor":"BriaCell Therapeutics Corporation","startDate":"2023-12-05","conditions":"Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm","enrollment":404},{"nctId":"NCT05616130","phase":"","title":"Pathological Myeloid Activation After Sepsis and Trauma","status":"RECRUITING","sponsor":"University of Florida","startDate":"2022-09-01","conditions":"Trauma Injury, Sepsis, Immunosuppression","enrollment":255},{"nctId":"NCT05733598","phase":"PHASE2","title":"Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC","status":"RECRUITING","sponsor":"Replimune Inc.","startDate":"2024-08-01","conditions":"Hepatocellular Carcinoma, Biliary Tract Cancer","enrollment":60},{"nctId":"NCT02379520","phase":"PHASE1","title":"HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2015-09","conditions":"Human Papillomavirus-Related Carcinoma, Human Papillomavirus Positive Oropharyngeal Carcinoma, Human Papillomavirus Positive Cervical Carcinoma","enrollment":32},{"nctId":"NCT06008093","phase":"PHASE3","title":"A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-04-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":280},{"nctId":"NCT06463665","phase":"PHASE2","title":"Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2024-09-26","conditions":"Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer","enrollment":142},{"nctId":"NCT03225794","phase":"","title":"Simian Foamy Virus Transmission to Humans","status":"RECRUITING","sponsor":"Institut Pasteur","startDate":"2010-11-01","conditions":"Simian Foamy Virus Infection (Disorder)","enrollment":1600},{"nctId":"NCT04013802","phase":"PHASE1","title":"TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2021-03-08","conditions":"Viral Infection","enrollment":47},{"nctId":"NCT01494103","phase":"PHASE1","title":"Administration of Donor T Cells With the Caspase-9 Suicide Gene","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2011-11","conditions":"Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia","enrollment":15},{"nctId":"NCT02510417","phase":"PHASE1","title":"Allogeneic Virus-specific T Cell Lines (VSTs)","status":"COMPLETED","sponsor":"Catherine Bollard","startDate":"2014-10-28","conditions":"Viral Infections After HSCT","enrollment":31},{"nctId":"NCT06070961","phase":"","title":"Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2024-05-07","conditions":"Follicular Lymphoma","enrollment":56},{"nctId":"NCT01430390","phase":"PHASE1","title":"In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-09","conditions":"Acute Lymphocytic Leukemia, Lymphoma","enrollment":19},{"nctId":"NCT02580539","phase":"PHASE1, PHASE2","title":"A Study of the Safety and Efficacy of EBV Specific T-cell Lines","status":"COMPLETED","sponsor":"Dr. Jean-Sebastien Delisle, MD, PhD","startDate":"2015-11","conditions":"Epstein-Barr Virus Infections, Post-Transplant Lymphoproliferative Disorder, Lymphoma","enrollment":12},{"nctId":"NCT03475212","phase":"PHASE1, PHASE2","title":"Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Transplantation & Cellular Therapy Consortium","startDate":"2018-06-20","conditions":"Cytomegalovirus Infections, Adenovirus Infection, EBV Infection","enrollment":52},{"nctId":"NCT05054361","phase":"","title":"Crosstalk Between Mucosal-Associated Invariant T (MAIT) Cells and the Gut Microbiota and Mucosa in the Development of Type 1 Diabetes in Children","status":"RECRUITING","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2022-01-01","conditions":"Type1diabetes","enrollment":180},{"nctId":"NCT05688241","phase":"PHASE1, PHASE2","title":"EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2026-11","conditions":"EBV Lymphoma, Post-transplant Lymphoproliferative Disease (PTLD)","enrollment":10},{"nctId":"NCT06551844","phase":"PHASE2","title":"Adaptive Dengue Antiviral Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"Oxford University Clinical Research Unit, Vietnam","startDate":"2025-09-01","conditions":"Dengue, Antiviral Drugs","enrollment":500},{"nctId":"NCT05648006","phase":"PHASE2","title":"First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer","status":"TERMINATED","sponsor":"Binhui Biopharmaceutical Co., Ltd.","startDate":"2023-10-17","conditions":"Advanced Colorectal Carcinoma","enrollment":7},{"nctId":"NCT04747522","phase":"","title":"Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Immune Kidney Transplant Study (COVID-19)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oslo University Hospital","startDate":"2021-01-22","conditions":"Kidney Transplant Infection, SARS-CoV Infection","enrollment":150},{"nctId":"NCT06088745","phase":"PHASE3","title":"A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine","status":"RECRUITING","sponsor":"Beijing Luzhu Biotechnology Co., Ltd.","startDate":"2023-09-28","conditions":"Vaccine-Preventable Diseases, Herpes Zoster","enrollment":4},{"nctId":"NCT02578641","phase":"PHASE3","title":"A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients","status":"COMPLETED","sponsor":"Tessa Therapeutics","startDate":"2014-07","conditions":"Nasopharyngeal Carcinoma","enrollment":330},{"nctId":"NCT02285062","phase":"PHASE3","title":"Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-02-17","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":570},{"nctId":"NCT05841342","phase":"","title":"Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH Patients","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2022-10-01","conditions":"Secondary Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection","enrollment":128},{"nctId":"NCT05765240","phase":"PHASE1","title":"The Effects of Topical Hyaluronic Acid and Laser Application on Wound Healing in Children","status":"UNKNOWN","sponsor":"Atlas University","startDate":"2023-02-27","conditions":"Wound Heal, Tooth Extraction Status Nos","enrollment":60},{"nctId":"NCT05064956","phase":"PHASE2","title":"Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study)","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2021-10-06","conditions":"Ebola Virus Disease, Ebola, Hiv","enrollment":26},{"nctId":"NCT01498484","phase":"PHASE2","title":"Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies","status":"COMPLETED","sponsor":"Atara Biotherapeutics","startDate":"2011-12","conditions":"EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma","enrollment":87},{"nctId":"NCT05589012","phase":"","title":"Evaluation of Viral Replication by Tonate Virus (TONV) and Zika Virus (ZIKV), Within an ex Vivo Trophoblast and Placental Model","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-11-01","conditions":"Zika Virus Infection","enrollment":8},{"nctId":"NCT03162224","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2017-06-26","conditions":"Head and Neck Cancer, Human Papilloma Virus","enrollment":35},{"nctId":"NCT04152486","phase":"PHASE3","title":"Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC","status":"UNKNOWN","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-11-14","conditions":"Ebola Virus Disease","enrollment":20426},{"nctId":"NCT02090374","phase":"NA","title":"Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2014-03","conditions":"Allergic Rhinitis, Asthma, Latent Tuberculosis","enrollment":93},{"nctId":"NCT01535885","phase":"PHASE1","title":"Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2012-02","conditions":"Epstein-Barr Virus Infections, Adenovirus, Cytomegalovirus Infections","enrollment":25},{"nctId":"NCT02973113","phase":"PHASE1","title":"Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2016-02-16","conditions":"NonHodgkin Lymphoma, Lymphoproliferative Disorders, EBV Related Lymphoma","enrollment":8},{"nctId":"NCT01447056","phase":"PHASE1","title":"Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2012-02","conditions":"Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Lymphoproliferative Disorder","enrollment":37},{"nctId":"NCT02510404","phase":"PHASE1","title":"Multivirus-specific Cytotoxic T Lymphocytes (mCTL)","status":"COMPLETED","sponsor":"Catherine Bollard","startDate":"2014-04","conditions":"Refractory Viral Infections","enrollment":1},{"nctId":"NCT02000817","phase":"PHASE1, PHASE2","title":"Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-03-12","conditions":"Diabetes Mellitus, Type 1","enrollment":30},{"nctId":"NCT01948180","phase":"PHASE2","title":"Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma","status":"TERMINATED","sponsor":"Cell Medica Ltd","startDate":"2014-09","conditions":"Lymphoma, Extranodal NK-T-Cell, EBV","enrollment":15},{"nctId":"NCT02313857","phase":"PHASE1","title":"Most Closely Human Leukocyte Antigen (HLA)-Matched CMV-specific T Lymphocytes (Viralym-C)","status":"COMPLETED","sponsor":"AlloVir","startDate":"2015-09","conditions":"CMV Infections","enrollment":10},{"nctId":"NCT02276820","phase":"PHASE1","title":"Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A)","status":"WITHDRAWN","sponsor":"AlloVir","startDate":"2017-12-07","conditions":"Adenovirus Infection","enrollment":""},{"nctId":"NCT02313844","phase":"PHASE1","title":"Most Closely Human Leukocyte Antigen (HLA)-Matched BK Virus-specific T Lymphocytes (Viralym-B)","status":"WITHDRAWN","sponsor":"AlloVir","startDate":"2018-03-01","conditions":"BK Virus Infection","enrollment":""},{"nctId":"NCT02115126","phase":"PHASE2","title":"Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant","status":"WITHDRAWN","sponsor":"David Rizzieri, MD","startDate":"2016-12","conditions":"Hodgkin Lymphoma, Non-Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT00711035","phase":"PHASE1, PHASE2","title":"Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2008-11","conditions":"Adenovirus Infection, EBV Infection","enrollment":50},{"nctId":"NCT00681824","phase":"PHASE2","title":"Fibrin Sealant for the Sealing of Dura Sutures","status":"COMPLETED","sponsor":"Baxter Healthcare Corporation","startDate":"2008-05","conditions":"Pathological Processes in the Posterior Fossa, Dura Defects","enrollment":95},{"nctId":"NCT01729221","phase":"","title":"Application of the Stem Cell Therapy in the End Stage Liver Disease and Assessment Its Consequences in the Quality of Live Style as Well as Development of HCC.","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2010-01","conditions":"Hepatocellular Carcinoma in Hepatitis C Virus Infected Patients","enrollment":280},{"nctId":"NCT00466258","phase":"PHASE4","title":"LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2006-10","conditions":"HIV Infections, Diffuse Large B Cell Lymphoma","enrollment":50},{"nctId":"NCT00698490","phase":"PHASE1, PHASE2","title":"Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1995-08","conditions":"Prophylaxis Herpes Simplex","enrollment":130}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Cell line and virus","genericName":"Cell line and virus","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}